Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization
NCT02975115
·
clinicaltrials.gov ↗
UNKNOWN
Status
102
Enrollment
OTHER
Sponsor class
Conditions
Chronic Myelocytic Leukemia
Interventions
OTHER:
RQ-PCR RNA Analysis
Sponsor
Seoul St. Mary's Hospital
Collaborators
[object Object]